Abstract Polycyclic aromatic hydrocarbons (PAHs) and their alkylated derivatives, such as methylnaphthalenes (MeNs), are harmful pollutants ubiquitously present in the environment. Exposure to PAHs has been linked to a variety of adverse health effects and outcomes, including cancer. Alkyl PAHs have been proposed as petrogenic source indicators because of their relatively high abundance in unburned petroleum products. We report a method to quantify 11 urinary methylnaphthols (Me-OHNs), metabolites of 1-and 2-methylnaphthalenes, and 10 monohydroxy PAH metabolites (OH-PAHs), using automated liquid-liquid extraction and isotope dilution gas chromatography tandem mass spectrometry (GC-MS/MS). After spiking urine (1 mL) with 13 C-labeled internal standards, the conjugated target analytes were hydrolyzed enzymatically in the presence of ascorbic acid. Then, their free species were preconcentrated into 20 % toluene in pentane, derivatized and quantified by GC-MS/MS. The 11 Me-OHNs eluted as 6 distinct chromatographic peaks, each representing 1−3 isomers. Method detection limits were 1.0− 41 pg/mL and the coefficients of variation in quality control materials were 4.7−19 %. The method was used to analyze two National Institute of Standards and Technology's Standard Reference Materials® and samples from 30 smokers and 30 non-smokers. Geometric mean concentrations were on average 37 (Me-OHNs) and 9.0 (OH-PAHs) fold higher in smokers than in non-smokers. These findings support the usefulness of Me-OHNs as potential biomarkers of nonoccupational exposure to MeNs and sources containing MeNs.
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Some PAHs and chemical mixtures containing PAHs, such as BaP, coal tar pitch, coke production, and chimney sweep soot, are classified as Group 1 human carcinogens by the International Agency for Research on Cancer [22] . Many other PAHs, including naphthalene, are probable or possible human carcinogens [23] . A recent study reported a doseresponse relationship between urinary naphthalene metabolites and chromosomal aberrations-established markers of cancer risk-in school-age children [24] . In addition, PAHs have been linked to a variety of adverse health effects and outcomes [3] . While toxicities and health effects associated with exposure to un-substituted PAHs have been widely studied, such information is limited on MeNs [19, 25] , even though the Agency for Toxic Substances and Disease Registry includes MeNs on its list of toxic substances [19] . A few animal studies on mice and in-vivo essays have indicated dose-and time-dependent lung toxicity after acute exposure to MeNs [26] [27] [28] [29] [30] [31] [32] ; the severity of lung toxicity associated from 2-MeN exposure was similar to that from naphthalene and worse than that from 1-MeN [27, 28, 33] .
In children and the general population from various countries [34] [35] [36] [37] [38] , and populations with high occupational exposure to PAHs [39, 40] , exposure has been assessed by measuring their monohydroxlated metabolites (OH-PAHs) in urine, with 1-hydroxypyrene (1-PYR) being the most commonly used exposure biomarker [41] [42] [43] [44] [45] . To the best of our knowledge, no studies have reported measurements of MeNs metabolites in human samples.
We report the development and validation of a method to quantify 11 methylnaphthols (Me-OHNs), metabolites of 1-MeN (n=5) and 2-MeN (n=6), as well as 10 OH-PAHs, metabolites of four un-substituted PAHs [i.e., naphthalene (n= 2), fluorene (n=3), phenanthrene (n=4), and pyrene (n=1)], in human urine. The method used enzymatic deconjugation, automated liquid-liquid extraction (LLE), and isotope dilution gas chromatography tandem mass spectrometry (GC-MS/ MS). The method was then used to quantify PAH and MeN metabolites in urine specimens from smokers and nonsmokers.
Methods and materials
Standards, chemicals, and supplies All reagents and solvents used were of the highest available grade or intended for pesticide residue analysis. Pentane and toluene (>99.8 %) were obtained from Tedia Company Inc. (Fairfield, OH, USA). Sodium acetate anhydrous (>99.0 %) was purchased from Fisher Scientific (Pittsburg, PA, USA), dodecane (99 %), ascorbic acid, N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA), and β-glucuronidase type H-1 with sulfatase activity (β-glucuronidase ≥300,000 units/g, sulfatase ≥10,000 units/g), isolated from Helix pomatia, were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ultrahigh purity nitrogen and helium were obtained from Airgas South Co. (Chamblee, GA, USA).
13 C 12 -2,3,3′,4,4′-pentachlorobiphenyl ( 13 C-PCB105) was purchased from Cambridge Isotope Laboratories (Andover, MA, USA). All native and 13 C-labeled OH-PAH and Me-OHN analytes, their abbreviations, and their suppliers are listed in Table 1 .
Stock solutions of individual OH-PAHs prepared from neat materials (ca. 1 mg/mL in acetonitrile) and purchased individual Me-OHN stock solutions (50 μg/mL in isooctane) were used to prepare standard mixtures for eight calibration standards at concentrations ranging from 1-1000 pg/μL, except for 1-hydroxynaphthalene (1-NAP) and 2-hydroxynaphthalene (2-NAP), which were present at four times higher concentrations (4-4000 pg/μL). The Sample preparation procedure Urine (1 mL) was fortified with 13 C-IS mixture (40 μL) using a Gilson 215 liquid handler (Gilson Inc., Middleton, WI, USA). The weight of the vial containing the 13 C-IS mixture was recorded before and after spiking of the sample run to calculate spiking accuracy for the run. Then, the urine was spiked with sodium acetate buffer (pH 5.5, 1 M, 1 mL) containing β-glucuronidase/sulfatase (3000 unit β-glucuronidase and 100 unit sulfatase activity/mL buffer) and ascorbic acid solution (10 μL, 250 mg/mL). After overnight incubation at 37°C (~18 h), the target analytes were extracted with a 20 % toluene 80 % pentane solvent mix (v/v) through automated LLE on a Gilson 215 liquid handler as described elsewhere [46] . In brief, deionized water (2 mL) and pentane/toluene mix (5 mL) were added to the urine and the samples were mixed by rotation for 5 min (20 rpm) using the automatic liquid handler. The procedure was paused and the samples were centrifuged for 20 min (2800 rpm). After the samples were returned to the liquid handler, the organic phase was transferred to collection tubes. This extraction procedure was repeated with additional pentane/toluene mix volume (5 mL). The combined pentane/toluene extracts were spiked with dodecane (10 μL) as a keeper, and concentrated on a RapidVap vacuum evaporator (Labconco Corporation, Kansas City, MO, USA), first at 40°C, 40 % vortex speed, and 500 mbar vacuum for 10 min to evaporate pentane, then at 70°C, 50 % speed, and 230 mbar to evaporate toluene until 10 μL remained (20 min). The concentrated extracts were reconstituted with toluene (20 μL), spiked with recovery standard solution 13 C-PCB105 (10 μL), and transferred to GC vials with 300-μL inserts. The target analytes were derivatized to their trimethylsilyl derivatives by adding MSTFA (10 μL) and incubating at 60°for 30 min.
Isotope dilution GC-MS/MS
GC-MS/MS analysis was carried out on an Agilent 7000B triple quadrupole mass spectrometer, interfaced with a 7890A gas chromatograph (Agilent Technologies, Santa Clara, CA, USA), operating in the multiple reaction monitoring (MRM) mode using electron impact ionization. One microliter of the extract was injected in splitless mode using a liner packed with glass wool to minimize column contamination at an inlet temperature of 270°C. The chromatographic separation was carried out on a Zebron ZB-5MS column (30 m×0.25 mm, 0.25 μm film thickness, Phenomenex Corp, Torrance, CA, USA), under a constant flow of 1 mL/min helium. The initial oven temperature was 95°C (1 min), then ramped at 15ºC/ min to 195ºC, 2ºC/min to 205°C and held for 3 min, and finally ramped at 40°C/min to 320°C and held for 3 min (total run time 22 min/sample). The transfer line and source temperatures were 270°C. In the triple quadrupole collision cell, helium was used as the quench gas at 2.25 mL/min and nitrogen was the collision gas at 1.5 mL/min. The instrument sensitivity was checked daily by injecting the lowest calibration standard (1 pg injected on column for 1-NAP and 2-NAP, and 250 fg for the remaining analyte). For the daily instrument sensitivity check to pass, the signal-to-noise (S/N) ratio needed to be at a minimum of 10 for all analytes. Table 1 lists the GC-MS/MS parameters, including precursor and product ions, collision energy and retention time, for all target analytes. Each of the 10 OH-PAH analytes is quantified with its corresponding 13 C-IS. All Me-OHN metabolites were quantified with 13 C 6 -2-methyl-1-naphthol as the internal standard. Identity of the Me-OHN peaks in urine samples was confirmed by the use of mass peak profiling [47] on a magnetic sector high-resolution mass spectrometer (MAT95XL; Thermo Fisher Scientific Inc. Waltham, MA, USA) at mass resolution of 10,000 (Supplementary Material, accurate mass peak profiling for peak confirmation).
Quality assurance and quality control Anonymously collected urine was pooled, pressure-filtered through 0.45 μm SuporCap-100 Capsule (Pall Corp. Ann Arbor, MI, USA), diluted with deionized water (1 part water to 4 parts of filtered urine), and used as a starting pool to make quality control (QC) materials. This pool was then divided and spiked with a standard mixture containing the target analytes in acetonitrile at two different levels to create two QC pools: low QC (spiked with 200 pg/mL) and high QC (spiked with 700 pg/ mL). The spiked urine pools were stirred at room temperature overnight, after which the QC materials were aliquoted into 16×100 mm glass culture tubes, and stored at -70°C until use. Each QC pool was characterized by producing 30 analytical runs over a period of three months to determine the 95 % and 99 % control limits. A multi-rule QC system was adopted to monitor within-and between-run variability for each analytical run using replicates of the two QC pools per run [48] . The concentrations of the QCs in each run were evaluated using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
In this method, one analytical run is defined as 34 unknown urine samples, two water blanks, two low QCs, two high QCs, and eight calibration standards, which are derivatized and analyzed in parallel with the urine extracts. For each sample, analyte results were considered valid when fulfilling the following criteria: (1) relative retention time, defined as the retention time ratio of a native analyte over its [48] .
Results and discussion
We developed a method to quantify 11 hydroxylated metabolites of 1-MeN and 2-MeN, along with 10 metabolites of four un-substituted PAHs, in human urine using automated LLE and isotope dilution GC-MS/MS determination. To the best of our knowledge, this is the first report of an analytical method for measuring MeN metabolites in urine and the first report of their concentrations in human urine samples. As expected, the Me-OHNs eluted shortly after the naphthols and before the hydroxyfluorenes (Fig. 1) . Although analytically this method could measure five additional compounds (1-methyl-2-naphthol, 2-methyl-1-naphthol, 8-methyl-1-naphthol, 9-hydroxyphenanthrene, 3-hydroxyfluoranthene), as shown in Fig. 1 , these compounds were not reported because of their instability and inconsistent QC results, which rendered them inadequate as exposure biomarkers.
GC-MS/MS of Me-OHNs
We evaluated several GC columns with various phase polarities from multiple manufactures for their separation Fig. 1 Gas chromatograms of (a) a standard (1 pg injection on column for 1-and 2-NAP, 250 fg for other analytes), and urine extracts from a non-smoker (b) and a smoker urine sample (c). Peaks represent the trimethylsilyl ethers of OH-PAHs and MeOHNs. Peaks marked with an asterisk are isomers that are not reported in this method. Calculated concentrations in urine samples (ng/mL) are given in parenthesis capabilities. On a ZB-5MS 5 % phenyl methyl silicone column, the 14 Me-OHNs eluted as eight distinct chromatographic peaks with each peak representing 1−3 isomers (Fig. 1) . Columns with intermediate polarity, such as RTX®-440 and RTX®-50 (Restek, Bellefonte, PA, USA), gave similar separation as the non-polar ZB-5MS (data not shown). RTX®-2330 (Restek), a polar column with its stationary phase consisting of 90 % biscyanopropyl/10 % cyanopropylphenyl polysiloxane, yielded the best separation in which the 14 MeOHNs were eluted as 11 chromatographic peaks (Supplementary Material, Figure S1 ). However, when using this column, the analytes elution slowed down. To maintain the separation for the rest of the analytes, the GC program run time had to be increased to 40 min. This led to broadened peak shape and reduced sensitivity for the late eluting analytes such as 1-PYR. Therefore, we chose a ZB-5MS column and reported the combined concentration of co-eluting metabolites. Such combined concentrations should provide a better estimation of MeN exposure than individual concentrations because 1-MeN and 2-MeN are both present in pyrogenic and petrogenic sources and both lead to multiple metabolites. However, for certain applications, such as to assess accidental exposure to specific MeNs, the RTX®-2330 column would provide a better separation of Me-OHN metabolites than the ZB-5MS column and thus facilitate the exposure assessment to 1-MeN or 2-MeN separately.
The mass spectrometer was at MRM mode. For most analytes, the molecular ion was chosen as the precursor ion, and M-30 (-2[·CH 3 ]), M-31 (-[·CH 3 +CH 4 ]), or M-89 (-OSiC 3 H 9 ) were selected as the product ions (Table 1 , Supplementary Material, Figure S2 ). During the method validation, a partially co-eluting interference affecting 4-hydroxyphenanthrene was present in certain urine samples. This interference was eliminated when using a different precursor-product ion pair, M-31 to M-46 (-[·CH 3 +·CH 3 + CH 4 ]), demonstrating the superior selectivity of MS/MS.
Enzymatic deconjugation
Like the OH-PAH metabolites [46] , preliminary data suggest that the Me-OHNs are excreted in urine predominantly as conjugates (data not shown). However, the method can only quantify the deconjugated metabolites because analytical standards are available for the hydroxyl metabolites, but not the conjugates. Therefore, it is essential to completely convert the conjugated metabolites to their free forms. This method used overnight hydrolysis of urine samples (1 mL) with 10 mg enzyme (3000 unit β-glucuronidase activity and 100 unit sulfatase activity) to reach complete deconjugation of all OH-PAHs [46] . This is consistent with the optimal condition (20,000 unit β-glucuronidase and 16 h hydrolysis for 10 mL artificial urine fortified with 1-PYR glucoronide) for 100 % deconjugation reported by Wegener et al. [49] . However, when we conducted deconjugation experiments on the MeOHNs, concentrations of several Me-OHNs, such as 4-methyl-1-naphthol (4M1N), decreased up to 50 % during the overnight hydrolysis (Fig. 2) . Potential explanations for such decrease include physical losses, such as those resulting from binding of the free species to the culture tube glass surface, or chemical changes, such as oxidation or photodegradation. After excluding glass binding and photodegradation (data not shown), we tested ascorbic acid as an antioxidant to prevent potential degradation by hydroxyl and superoxide radicals [50] [51] [52] , and found that ascorbic acid effectively stabilized the Me-OHNs during the hydrolysis process by preventing the oxidation of the deconjugated Me-OHNs (Fig. 2) . We further determined 2.5 mg ascorbic acid per 1 mL urine as the appropriate amount to ensure that all MeOHNs were stable during the enzymatic hydrolysis.
Method improvement
In addition to the inclusion of Me-OHNs, the current method improved the quantification of urinary OH-PAHs, including 1-PYR, compared with the previous method [46] . First, the automated 13 C-IS spiking improved accuracy and precision (data not shown), and eliminated potential human error in this critical step. The 13 C-IS spiking accuracy was calculated and monitored as an additional quality assurance check for an analytical run. Second, the solvent selection choice maximized extraction efficiencies, reduced losses during samples preparation, and, therefore, increased method recoveries. The recoveries were 52 % and 53 % for the two 13 C-naphthols and 69 %-100 % for the eight larger 13 C-labeled OH-PAHs, compared with 46 %-72 % in the previous method [46] . Third, the method incurred reduced cost and increased productivity by using a considerably cheaper and more robust instrumentation (MS/MS versus high resolution mass spectrometry). Fourth, the method gave increased sensitivity of the OH-PAH analytes, as demonstrated by higher S/N ratios for the lowest standard (Supplementary Material, Figure S3) . Finally, the presence of ascorbic acid facilitated the deconjugation of several OH-PAH conjugates (i.e., those of 1-NAP and 9-hydroxyfluorene [46] ). The hydrolysis of these conjugates was inefficient compared with other OH-PAHs, potentially because of steric hindrance and higher composition of sulfate conjugate [46] . In addition, 9-FLU is an alcohol rather than a phenol, which might affect the deconjugation efficiency. The use of ascorbic acid increased the deconjugation speed, most likely by preventing the oxidative damage of β-glucuronidase and sulfatase [50] , and thus reduced deconjugation time required to achieve maximal yield from overnight to 3 h (Supplementary Material, Figure S4 ). All of these characteristics together are essential for conducting large epidemiological studies such as the National Health and Nutrition Examination Survey.
Our previous analytical method [46] targeted 24 urinary OH-PAHs, namely the 10 OH-PAHs reported in this method and monohydroxyl derivatives of BaP, chrysene, benz(a)anthracene, and benzo(c)phenanthrene, including 3-hydroxybenzo[a]pyrene (3-BaP), with the limit of detection (LOD) for 3-BaP at 2.6 ng/L [53] . However, these relatively large PAHs are mainly excreted through feces [3] . Therefore, their urinary monohydroxyl metabolites may not be optimal exposure biomarkers as suggested by the rather infrequent detection of these compounds in the Canadian and US national surveys [36, 38] and in other studies [54, 55] . For example, 3-BaP had a detection rate of 0 % in all demographic groups in the Canadian Health Measures Survey (LOD: 2 ng/L) [38] . With a more sensitive method (LOD: 0.1 ng/L) [56] , Lafontaine et al. detected 3-BaP in 18.5 % of non-smokers and 66.7 % of smokers (13-50 cigarettes/d), and acknowledged nonetheless that the use of 3-BaP as PAH exposure biomarker was less justified [57] . To avoid misinterpretation during exposure assessment, we discontinued the measurement of monohydroxyl derivatives of the larger PAHs, including 3-BaP, and reported 10 detectable and stable urinary OH-PAHs (i.e., metabolites of naphthalene, fluorene, phenanthrene, and pyrene) in this method and in all recent research projects [58, 59] .
Method evaluation and validation
The LOD for this method was defined as three times of S 0 , where S 0 is the standard deviation (SD) as the concentration approaches zero [60] . Because OH-PAHs and Me-OHNs are ubiquitous contaminants in urine, we spiked synthetic urine with four different levels of standard mixtures (10, 20, 50 , and 100 pg/mL; 40-400 pg/mL for 1-and 2-NAP) and performed six repeated measurements to determine the SD at each level. The SD was then plotted as a function of concentration and S 0 was extrapolated as the intercept of the regression line [60] . LODs were 7.0−41 pg/mL for the Me-OHNs and 1.0−19 pg/ mL for the OH-PAHs ( Table 2 ).
The overall coefficients of variation from 30 runs of low QC and high QC over a 3-mo period, shown in Table 2 , were 4.7 %−13 % for the OH-PAHs and 11 %−19 % for the MeOHNs. The variability for the Me-OHNs was in general higher than that of the OH-PAHs, likely because only one 13C-IS is available for the Me-OHNs. As expected, the between-day variability is higher than the within-day variability.
The accuracy of the proposed method was evaluated in a 6-point matrix standard addition experiment. A urine pool was spiked with 10, 20, 50, 100, 500, and 1000 pg/mL of standards (four times higher spike for 1-NAP and 2-NAP). The unspiked and spiked urine pools were analyzed, each in six replicates. A linear regression analysis was carried out by plotting the measured concentrations against spiked concentrations to evaluate correlations and determine concentrations of analyte in the nonspiked urine sample. As shown in Table 2 , the method gave good linearity for all compounds with correlation coefficients ranging 0.97−1.00. The intercept from the linear regression reflected 80 %−109 % of the measured concentrations in the unspiked urine pool and the differences were not statistically significant (alpha=0.05), demonstrating a non-biased and accurate method.
The accuracy of this method was further evaluated through two NIST SRMs, namely SRM 3672 (smoker urine) and SRM 3673 (non-smoker urine). As shown in Table 3 , the results on OH-PAHs from this method were in good agreement with the certified concentrations (Draft Certificates of Analysis, internal communication with Dr. Michele Schantz, NIST) that spanned several orders of magnitude, further demonstrating the accuracy of the proposed method.
Analysis of smoker and non-smoker samples Table 4 lists the geometric mean (GM) and selected percentile urinary concentrations in 30 self-identified smokers and 30 non-smokers, as well as the OH-PAH concentrations in the general, non-smoking and smoking US population [36] . As expected, OH-PAH concentrations were on average 9.0 (range: 3.9-25) fold higher in smokers than non-smokers. For example, the GM concentrations of 1-PYR, the most commonly used PAH exposure biomarker, were 58 and 482 ng/L in the non-smoker and smoker samples, respectively, corresponding to 8.3 fold difference between these two groups. Me-OHNs were detected in 53-97 % of nonsmokers and 100 % of smokers. As shown in Table 4 , the GM concentrations for Me-OHNs ranged from 34-453 pg/mL in the non-smokers to 1608-6990 pg/mL in the smokers, which corresponds to an average of 36.7-fold (range: 9.9-61) difference.
Interestingly, the concentration differences between smokers and non-smokers of Me-OHNs are even higher than those of OH-PAHs, the commonly recognized PAH exposure biomarkers. In the 30 non-smokers, the GM urinary concentrations of MeN metabolites (sum of 11 MeOHNs; 1.7 ng/mL) were lower than those of the naphthalene metabolites (sum of 1-NAP and 2-NAP; 5.8 ng/mL). In the 30 smokers, the GM concentrations of the metabolites from naphthalene and MeNs were comparable, at 33.7 and 33.4 ng/mL, respectively (Supplementary Material, Figure S5 ). Similarly, the Me-OHN concentrations were 10.9-30.0 times higher in the NIST smoker urine SRM than the non-smoker urine SRM, whereas for the OH-PAHs, the differences were smaller (0.2-fold to 11.0-fold). These results were consistent with the report that a higher amount of methyl PAHs, such as MeNs, were generated in tobacco 1760 510  911  1280 12400 9640  14100 21300 2190 1520  6290  2  2-NAP  2130 1310  1930 2700 19900 12500 20800 32500 2620 1680  8600  3  9-FLU  243  100  189  603  1252  750  1126  1928  230  200  342  4  3-FLU  52  24  48  78  1321  968  1429  2168  138  90  592  5  2-FLU  138  68  133  205  2000  1440  2030  2930  333  236  990  6  4-PHE  16  <LOD 15  29  85  54  92  119  43  39  53  7  3-PHE  53  22  49  84  380  275  348  592  105  91  194  8  1-PHE  84  38  84  144  330  241  326  452  145  132  193  9  2-PHE  42  16  38  70  169  103  169  245  56  48  88  10  1-PYR  58  22  47  94  482  288  425  872  47  40  104  11  7M1N_3M1N_8M2N 152  60  148  272  4920  3690  4540  11600 ---12  3M2N_6M1N  419  245  375  653  5660  3530  5560  9570  ---13  4M1N  123  64  114  219  6990  4840  8090  12700 ---14  5M1N  106  47  100  313  6420  4270  8200  12900 ---15  4M2N_6M2N_7M2N 453  201  404  1760 4490  2980  4770  8380  ---16  5M2N  34  <LOD 23  81  1610  1030  1980  3220  --- a Geometric mean in US adults, and least square geometric means in US non-smokers and smokers are referenced from [36] . Mass fraction concentrations (μg/kg) were converted to urinary concentration (pg/mL) using a urine density value of 1.019 g/mL, as specified on the COAs smoking compared with other combustion sources [4, 5] , and strongly suggested the utility of urinary Me-OHNs as biomarkers to assess human exposure to MeNs.
Conclusions
To the best of our knowledge, this is the first method reporting the concurrent measurement of 11 metabolites of MeNs and 10 metabolites of unsubstituted PAHs in 1 mL of human urine with optimal precision, accuracy, and sensitivity. The automated sample preparation permits robust operation and high throughput, essential for the analysis of samples in national surveys and other large epidemiological studies. We evaluated the usefulness of the method to assess exposure to PAHs by analyzing urine specimens from smokers and non-smokers, two populations known to have different levels of PAH exposure. It should be noted that many factors, such as urine dilution, demography, geography, and timing of sample collection, can affect metabolite concentrations. Nonetheless, the magnitude of concentration differences between smokers and non-smokers, especially for Me-OHNs, strongly suggest the utility of these compounds as potential biomarkers for assessing exposure to PAHs, MeNs, and related sources.
